186497-07-4
[1]Patent:US5866568,1999,A
[1]Patent:WO2007/10235,2007,A1.Locationinpatent:Page/Pagecolumn21
186497-07-4
[1]Patent:WO2007/10235,2007,A1.Locationinpatent:Page/Pagecolumn6;20
[2]Patent:WO2007/10235,2007,A1.Locationinpatent:Page/Pagecolumn20-21
[1]Patent:WO2007/10235,2007,A1.Locationinpatent:Page/Pagecolumn22-23
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Journal: Cancer 20121115
Title: The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Journal: Life sciences 20121015
Title: Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Journal: BJU international 20120901
Title: Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012.
Journal: Molecules (Basel, Switzerland) 20120827
Title: Novel options for the treatment of castration-resistant prostate cancer.
Journal: World journal of urology 20120801
Title: Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
Journal: The Journal of urology 20120701
Title: Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20120701
Title: New developments in castrate-resistant prostate cancer.
Journal: BJU international 20120601
Title: Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20120401
Title: Targeting the endothelin axis in prostate carcinoma.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20120401
Title: Castration-resistant prostate cancer: systemic therapy in 2012.
Journal: Clinics (Sao Paulo, Brazil) 20120401
Title: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Journal: Journal of the National Cancer Institute 20120222
Title: Emerging treatment options for patients with castration-resistant prostate cancer.
Journal: The Prostate 20120201
Title: Castration-resistant prostate cancer: mechanisms, targets, and treatment.
Journal: Prostate cancer 20120101
Title: Emerging targeted therapies for castration-resistant prostate cancer.
Journal: Frontiers in endocrinology 20120101
Title: Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110920
Title: Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Journal: The Prostate 20110901
Title: The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20110901
Title: Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Journal: European journal of cancer (Oxford, England : 1990) 20110801
Title: The metabolism of [14C]-zibotentan (ZD4054) in rat, dog and human, the loss of the radiolabel and the identification of an anomalous peak, derived from the animal feed.
Journal: Journal of pharmaceutical and biomedical analysis 20110601
Title: A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Journal: Cancer chemotherapy and pharmacology 20110501
Title: Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110415
Title: Emerging novel therapies in the treatment of castrate-resistant prostate cancer.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20110401
Title: Castration-resistant prostate cancer: targeted therapies and individualized treatment.
Journal: The oncologist 20110301
Title: Current treatment strategies for castration-resistant prostate cancer.
Journal: Korean journal of urology 20110301
Title: A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Journal: Investigational new drugs 20110201
Title: Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Journal: BMC clinical pharmacology 20110101
Title: Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Journal: Journal of hematology & oncology 20110101
Title: Therapeutic targets for bone metastases in breast cancer.
Journal: Breast cancer research : BCR 20110101
Title: Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Journal: Clinical Medicine Insights. Oncology 20110101
Title: Docetaxel-based combination therapy for castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20101101
Title: Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.
Journal: International journal of clinical pharmacology and therapeutics 20101101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20101101
Title: Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
Journal: BJU international 20101001
Title: ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Journal: Breast cancer research and treatment 20100901
Title: Zibotentan for the treatment of castrate-resistant prostate cancer.
Journal: Expert opinion on investigational drugs 20100701
Title: An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Journal: Clinical therapeutics 20100701
Title: Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Journal: Canadian journal of physiology and pharmacology 20100601
Title: Update on castrate-resistant prostate cancer: 2010.
Journal: Current opinion in oncology 20100501
Title: [New drugs in metastatic castration-resistant prostate cancer].
Journal: Bulletin du cancer 20100101
Title: Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Journal: Clinical interventions in aging 20100101
Title: In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20090601
Title: Emerging therapies in castrate-resistant prostate cancer.
Journal: Current opinion in oncology 20090501
Title: ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
Journal: Expert opinion on investigational drugs 20080801
Title: Endothelin receptor antagonists in cancer therapy.
Journal: Cancer investigation 20071201
Title: Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Journal: Cancer research 20070701
Title: Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.
Journal: British journal of cancer 20050620
